Practical Saudi Guidelines on management of moderate-to-severe psoriasis: 2026 update.

In 30 seconds

This systematic review developed updated clinical practice guidelines for managing moderate-to-severe psoriasis in Saudi Arabia, addressing both adults and pediatric patients. The guidelines include 27 evidence-based recommendations, emphasizing the use of PASI 90 as the primary treatment goal. Biologic therapies are recommended for better disease control.

Key findings

• 27 evidence-based recommendations were established for managing moderate-to-severe psoriasis.
• PASI 90 is strongly recommended as the primary treatment goal over PASI 75.
• For adults, biologic therapies like IL-17 and IL-23 inhibitors are recommended.
• Pediatric patients should receive early initiation of biologic therapy with preferred options including etanercept and secukinumab.

Why it matters

These guidelines provide a structured approach to managing moderate-to-severe psoriasis, ensuring that clinicians have access to the latest evidence-based practices for both adult and pediatric populations.